Swiss drugmaker Sandoz settles US anti-trust charges
NewsletterReceive the most important news of the day by email
The Swiss generic drugs manufacturer Sandoz has agreed to pay more than
$500 million to settle legacy United States anti-trust legal issues.
20 hours ago
from: SWI swissinfo.ch
- Sandoz settles US antitrust case for $275m Sandoz (SIX:SDZ), a division of Novartis (SIX:NOVN), has reached a $275
million settlement agreement with the end payer plaintiffs in a US...
from: Investing.com
- Sandoz: measures to resolve US antitrust dispute Sandoz today announced a series of steps aimed at resolving the U.S.
generic antitrust class action litigation. Sandoz has reached a...
from: marketscreener.com